Abstract Search

ea0099ep449 | Pituitary and Neuroendocrinology | ECE2024

Patient reported perspectives of disease burden in acromegaly: data from the acromegaly community patient-focused drug development meeting

Agrawal Nidhi , CJ Yuen Kevin , Bonert Vivien , Huang Wenyu , Sisco Jill

Acromegaly is a rare disease most commonly caused by benign pituitary adenomas producing excess growth hormone. A profound mismatch between biological control and symptom control creates a high disease burden despite optimal disease management. To learn more about the patient experience, Acromegaly Community hosted a virtual Externally Led Patient-Focused Drug Development meeting in January 2021. There were 304 registered attendees, including 128 people with acromegaly and the...

0 shares

ea0073pep3.2 | Presented ePosters 3: Pituitary and Neuroendocrinology | ECE2021

Safety results from MPOWERED, a phase 3 trial of oral octreotide capsules in adults with acromegaly

Freda Pamela U. , Fleseriu Maria , Dreval Alexander V. , Pokramovich Yulia , Bondar Irina , Isaeva Elena , Huang Wenyu , Molitch Mark E. , Macut Djuro P. , Leonova Nina , Raverot Gerald , Yossi Gilgun-Sherki , Ludlam William H. , Patou Gary , Haviv Asi , Gordon Murray B. , Biermasz Nienke , Melmed Shlomo K. , Strasburger Christian J.

BackgroundInjectable somatostatin receptor ligands (iSRLs) have been a mainstay in acromegaly treatment. Oral octreotide capsules (OOC; MYCAPSSA®) were recently approved in the USA. Results from the placebo-controlled CHIASMA OPTIMAL and open-label CH-ACM-01 studies showed an OOC safety profile consistent with that of iSRLs with no new or unexpected safety signals. Results of the MPOWERED trial have enabled a comparison of OOC safety and ...

0 shares

Endocrine Abstracts

Patient reported perspectives of disease burden in acromegaly: data from the acromegaly community patient-focused drug development meeting

Safety results from MPOWERED, a phase 3 trial of oral octreotide capsules in adults with acromegaly

BiosciAbstracts